Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 12/23/20
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell TherapiesGlobeNewsWire • 12/15/20
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of HematologyGlobeNewsWire • 12/07/20
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of HematologyGlobeNewsWire • 12/06/20
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual MeetingGlobeNewsWire • 12/05/20
Allogene Therapeutics (ALLO) Up 8.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/20
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020GlobeNewsWire • 12/02/20
Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference ParticipationGlobeNewsWire • 11/12/20
Allogene Therapeutics' (ALLO) CEO David Chang on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/04/20
Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of HematologyGlobeNewsWire • 11/04/20
Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020GlobeNewsWire • 10/27/20
Allogene Therapeutics Announces October 2020 Virtual Investor Conference ParticipationGlobeNewsWire • 10/01/20
Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/04/20
Allogene Therapeutics Announces September 2020 Virtual Investor Conference ParticipationGlobeNewsWire • 09/02/20
Allogene Therapeutics' (ALLO) CEO David Chang on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020GlobeNewsWire • 07/28/20
Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D.GlobeNewsWire • 07/07/20